SCHEDULE 13G: Ikarian Capital and Neil Shahrestani Disclose 9.5% Passive Stake in Forte Biosciences

Investment firm Ikarian Capital, along with Neil Shahrestani, has reported a 9.5% beneficial ownership stake in Forte Biosciences, Inc., holding 609,225 shares as of December 31, 2024.

Summary

• Ikarian Capital, LLC and Neil Shahrestani (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Forte Biosciences, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 609,225 shares of Forte Biosciences' Common Stock.
• This ownership represents 9.5% of the Issuer's outstanding Common Stock, based on 6,393,323 shares outstanding as of December 30, 2024, as reported by Forte Biosciences in a Form 8-K filed on January 24, 2025.
• Ikarian Capital, LLC, a Delaware limited liability company, serves as an investment adviser to Ikarian Healthcare Master Fund, L.P., and certain separately managed accounts, which are the record owners of the securities.
• Neil Shahrestani indirectly controls Ikarian Capital, LLC and is therefore deemed to indirectly beneficially own the securities.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the document itself is a factual disclosure, the presence of a significant passive institutional investor can be viewed as a positive signal of confidence in the company, without implying any immediate negative or activist intentions.

Positives

• The disclosure of a significant 9.5% stake by an institutional investor like Ikarian Capital may signal confidence in Forte Biosciences' long-term prospects.
• The filing explicitly states the investment is passive, held in the ordinary course of business, and not for the purpose of changing or influencing control, which can provide stability and reduce concerns about potential activist interventions.

Risks

• The document states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, which mitigates the risk of an activist investor seeking to force strategic changes.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Forte Biosciences' future operations or financial performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Neil Shahrestani on behalf of Ikarian Capital, LLC and himself)

Industry Context

Forte Biosciences, Inc. operates in the biotechnology or pharmaceutical sector, as indicated by the investment vehicle 'Ikarian Healthcare Master Fund, L.P.' This filing is a routine disclosure of a significant passive investment by a specialized healthcare investment firm.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder and confirms the passive nature of their investment, which may offer some stability.
• Company Management: Awareness of a large, passive institutional investor on their shareholder register.

Key Dates

Keywords

Forte Biosciences, Ikarian Capital, Neil Shahrestani, SEC filing, Schedule 13G, beneficial ownership, common stock, investment adviser, passive investment, healthcare